Texas Firm Secured Exclusive U.S. Ibogaine License
The agreement positions the company to develop and distribute pharmaceutical-grade ibogaine across the United States.
Updated on Sept. 28, 2026 in Substance Abuse
Live Poll
Should private companies be responsible for leading research into experimental ibogaine treatments?
Texas Ibogaine Research Corporation has signed a binding term sheet for exclusive rights to develop and distribute PsyLabs' pharmaceutical-grade ibogaine in the United States. This agreement provides the subsidiary with access to technical documentation and extraction methods for future development programs.
Why it matters
Securing this license establishes a formal path for the company to pursue a United States ibogaine development program using standardized, pharmaceutical-grade materials. The move allows the subsidiary to leverage existing regulatory documentation to advance its work in the U.S. market.
The agreement outlines up to US$1.3 million in milestone payments for the first drug candidate, covering exclusive U.S. distribution and supply rights. The regulatory and development path remains under investigation as the parties work toward a definitive contract.
The players
Texas Ibogaine Research Corporation
A Texas-based subsidiary of Psyence Biomedical Ltd. focused on the development of ibogaine for the United States market.
PsyLabs
A pharmaceutical developer that produces ibogaine and maintains proprietary extraction and manufacturing methods.
Psyence Biomedical Ltd.
A biotechnology company that holds an ownership interest in both PsyLabs and its subsidiary, Texas Ibogaine Research Corporation.
The details
The partnership grants Texas Ibogaine Research Corporation access to PsyLabs’ proprietary extraction methods and technical know-how. Under the terms, the subsidiary will source all of its U.S. ibogaine requirements exclusively from PsyLabs to ensure pharmaceutical-grade consistency. The deal also incorporates a margin-sharing arrangement for any product resold within the United States.
Timeline
September 28, 2026: Texas Ibogaine Research Corporation and PsyLabs entered into a binding term sheet.
November 30, 2026: Deadline for the parties to conclude a definitive agreement.
Health Landscape
This development represents a preliminary organizational step toward establishing a standardized supply chain for ibogaine in the United States. It follows an industry-wide trend of increasing investment in regulated, pharmaceutical-grade psychedelic compounds for potential therapeutic use.
This news indicates an early stage of corporate development and does not represent an available treatment for any medical condition. Any inquiries regarding current treatment options or emerging research in this field are best discussed with your primary care physician.
The takeaway
This agreement creates a framework for future U.S. research by securing a supply of pharmaceutical-grade ibogaine. Patients should remain aware that these development programs are long-term processes and currently offer no clinical changes to standard care.
What happens next
The parties have until November 30, 2026, to finalize and sign a definitive agreement, at which point the term sheet will lapse if not completed.
Further reading
Learn more about the latest research and regulatory shifts in Substance Abuse treatment developments.
Live Poll
Should private companies be responsible for leading research into experimental ibogaine treatments?
